The Cancer Screening Research Network (CSRN) will investigate how to identify cancers earlier, when they may be easier to treat, to ultimately save lives. In late 2024, CSRN plans to launch the Vanguard Study on Multi-Cancer Detection, a pilot study to inform the design of a larger trial of multi-cancer detection tests.
W. Kimryn Rathmell, M.D., Ph.D., begins her tenure as the 17th director of the National Cancer Institute on December 18, 2023. She comes to NCI from Vanderbilt University Medical Center in Nashville, Tennessee, where she served as the Hugh Jackson Morgan Chair in Medicine, chair of the Department of Medicine, and physician-in-chief.
New approach may increase the effectiveness of T-cell-based immunotherapy treatments against solid tumors.
Steven A. Rosenberg, M.D., Ph.D., has been awarded the National Medal of Technology and Innovation by President Biden. It is the nation's highest honor for technological achievement.
New diagnoses of six major cancer types fell in the early part of the pandemic, according to findings from part 2 of the latest Annual Report to the Nation on the Status of Cancer.
NCI’s Clinical Proteomic Tumor Analysis Consortium releases proteogenomic dataset to accelerate cancer discoveries.
An NCI study shows that cell division can be interrupted by withdrawing growth-promoting signals early on in the process.
NCI has awarded $50 million to establish five new centers to study interventions for improving cancer outcomes in persistent poverty communities.
ComboMATCH will consist of numerous phase 2 cancer treatment trials that aim to identify promising drug combinations that can advance to larger, more definitive clinical trials.
A new study has outlined opportunities for achieving President Biden and First Lady Biden’s Cancer Moonshot goal of reducing the cancer death rate by at least 50% over the next 25 years.